# Colchicine (cardiovascular)

Colchicine is a plant alkaloid from the autumn crocus (Colchicum autumnale). It fights inflammation by binding tubulin and disrupting microtubules. That hampers neutrophil migration and blocks assembly of the NLRP3 inflammasome, a complex that makes IL-1β and IL-18, two cytokines tied to plaque progression. At just 0.5 mg once a day (far below gout doses), it calms chronic vascular inflammation without broadly suppressing your immune system. Its relevance to aging is inflammaging: the low-grade, sterile inflammation that builds with age and speeds heart disease. Colchicine is a tool to interrupt one causal path from aging to major heart events (MACE). The trial evidence is strong. COLCOT (4,745 patients) showed a 23% relative drop in MACE when started within 30 days of a heart attack (Tardif et al., NEJM 2019). LoDoCo2 (5,522 patients) showed a 31% drop in heart events in stable coronary disease over a median 28.6 months (Nidorf et al., NEJM 2020). The FDA approved colchicine 0.5 mg (Lodoco) in June 2023 for secondary heart prevention. The 2023 AHA/ACC guideline gives it a Class IIb recommendation for residual inflammatory risk. Gut side effects are the main tolerability issue, and combining it with CYP3A4/P-gp inhibitors needs dose care.

## Sources

- Nidorf SM, Fiolet ATL, Mosterd A, et al.. (2020). Colchicine in Patients with Chronic Coronary Disease. New England Journal of Medicine. https://doi.org/10.1056/NEJMoa2021372
- Tardif JC, Kouz S, Waters DD, et al.. (2019). Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction. New England Journal of Medicine. https://doi.org/10.1056/NEJMoa1912388
- Virani SS, Newby LK, Arnold SV, et al.. (2023). 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease. Circulation. https://doi.org/10.1161/CIR.0000000000001168

---

_Canonical: https://longevity-switzerland.com/en/glossary/colchicine · Part of Longevity Cities · Updated 2026-06-22_